BioTuesdays

Author - Sydney Stewart

Onconova Logo

HCW cuts Onconova Therapeutics to neutral; removes PT

H.C. Wainwright downgraded Onconova Therapeutics (NASDAQ:ONTX) to “neutral” from “buy” without a price target after the company’s Phase 3 INSPIRE trial with rigosertib in high-risk myelodysplastic syndromesfailed on...

Maxim ups TFF Pharma PT to $18 from $12

Maxim Group raised its price target for TFF Pharmaceuticals (NASDAQ:TFFP) to $18 from $12, citing a new partnership with Union Therapeutics that further validates TFF’s platform potential. The stock closed at $11.55 on...

HCW starts Lumos Pharma at buy; PT $33

H.C. Wainwright initiated coverage of Lumos Pharma (NASDAQ:LUMO) with a “buy” rating and $33 price target. The stock closed at $13.80 on Aug. 3. Analyst Edward White writes that the company’s LUM-201 drug candidate is...

Onconova Logo

Maxim ups Onconova Therapeutics PT to $3 from $1.25

Maxim Group raised its price target for Onconova Therapeutics (NASDAQ:ONTX) to $3 from $1.25 after the company announced that the required number of survival events for the pivotal Phase 3 INSPIRE study of IV rigosertib...

SVB Leerink starts Immatics at OP; PT $17

SVB Leerink initiated coverage of Immatics (NASDAQ:IMTX) with an “outperform” rating and $17 price target. The stock closed at $10.57 on July 24. Immatics is developing T-cell receptor (TCR)-based immunotherapies and...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.